• An inhibitor of RTKs, including ALK, MET, ROS1, and RON
    • FDA approved for locally advanced or metastatic ALK-positive NSCLC
    • Recommended dose: 250 mg orally twice daily
    • Half-life: 42 hours
    • Metabolism: Major CYP3A4 substrate and P-glycoprotein
    • Common side effects: Vision problems (diplopia, blurred vision), nausea/vomiting, diarrhea, dysphagia, GE reflux disease, reflux esophagitis, swelling of hands or feet, fatigue, dizziness, transaminitis (ALT increase)
    • Clinical pearls: Advise patients to exercise caution when driving or operating machinery because of the risk of developing visual changes such as floaters, blurred vision, light sensitivity, or flashes of light.
    Other topics in Targeted and Immunotherapy Agents